Patents by Inventor Bart Barlogie
Bart Barlogie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200392587Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: August 24, 2020Publication date: December 17, 2020Applicant: BioVentures, LLCInventors: Bart BARLOGIE, Pingping QU, Christoph HEUCK, Joshua EPSTEIN
-
Publication number: 20200291486Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: ApplicationFiled: March 20, 2020Publication date: September 17, 2020Applicant: BIOVENTURES, LLCInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Publication number: 20200270691Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogenesis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: ApplicationFiled: February 28, 2020Publication date: August 27, 2020Applicant: BioVentures, LLCInventors: John D. Shaughnessy, JR., Bart Barlogie, Fenghuang Zhan
-
Patent number: 10752956Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: GrantFiled: November 17, 2017Date of Patent: August 25, 2020Assignee: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Patent number: 10597729Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: GrantFiled: May 12, 2017Date of Patent: March 24, 2020Assignee: BIOVENTURES, LLCInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Patent number: 10577656Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: February 17, 2017Date of Patent: March 3, 2020Assignee: BIOVENTURES, LLCInventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Publication number: 20180171414Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: November 17, 2017Publication date: June 21, 2018Applicant: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Publication number: 20180080079Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: ApplicationFiled: February 17, 2017Publication date: March 22, 2018Applicant: BioVentures, LLCInventors: John D. Shaughnessy, JR., Bart BARLOGIE, Fenghuang Zhan
-
Publication number: 20170342501Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: ApplicationFiled: May 12, 2017Publication date: November 30, 2017Applicant: BIOVENTURES, LLCInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Patent number: 9822419Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: GrantFiled: May 19, 2014Date of Patent: November 21, 2017Assignee: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Patent number: 9714451Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: September 27, 2013Date of Patent: July 25, 2017Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Patent number: 9650677Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: GrantFiled: May 21, 2013Date of Patent: May 16, 2017Assignee: BIOVENTURES, LLCInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Patent number: 9574238Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: May 22, 2013Date of Patent: February 21, 2017Assignee: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Publication number: 20160102362Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: May 19, 2014Publication date: April 14, 2016Inventors: Bart BARLOGIE, Pingping QU, Christoph HEUCK, Joshua EPSTEIN
-
Publication number: 20150140016Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods for treating multiple myeloma, for restoring osteoprotegerin (OPG) expression in a cell, for inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) expression in a cell, and for increasing bone mass in a subject. These methods utilize a DKK1 neutralizing antibody, an anti-sense oligonucleotide against a DKK1 gene, or a shRNA against a DKK1 gene to inhibit the activity of the DKK1 protein.Type: ApplicationFiled: January 30, 2015Publication date: May 21, 2015Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: John D. Shaughnessy, JR., Bart Barlogie, Ya-Wei Qiang
-
Patent number: 8992909Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.Type: GrantFiled: February 22, 2012Date of Patent: March 31, 2015Assignee: Board of Trustees of the University of ArkansasInventors: John D Shaughnessy, Jr., Bart Barlogie, Ya-Wei Qiang
-
Patent number: 8954283Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogenesis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: October 6, 2009Date of Patent: February 10, 2015Inventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Patent number: 8843320Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: GrantFiled: May 20, 2005Date of Patent: September 23, 2014Assignee: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Publication number: 20140179545Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: ApplicationFiled: September 27, 2013Publication date: June 26, 2014Applicant: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, JR., Bart Barlogie, Fenghuang Zhan
-
Publication number: 20130345080Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: ApplicationFiled: May 22, 2013Publication date: December 26, 2013Applicant: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, JR., Bart Barlogie, Fenghuang Zhan